The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.
 
Anne C. Chiang
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Flatiron Health; Genentech; Genentech; Genentech/Roche; Jazz Pharmaceuticals; regeneron; Sanofi/Regeneron
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Millennium; OncoMed; Onyx; Stem CentRx
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
Matthew Austin
No Relationships to Disclose
 
Tyler F. Stewart
Consulting or Advisory Role - Seattle Genetics/Astellas
Research Funding - GRAIL
 
Mohammad Arammash
No Relationships to Disclose
 
Sunil Bhatt
No Relationships to Disclose
 
Scott N. Gettinger
Research Funding - ARIAD/Takeda (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck (Inst); NextCure (Inst)
 
Sarah B. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genzyme; Janssen; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Frederick Hugh Wilson
Consulting or Advisory Role - Loxo
Research Funding - Agios
 
Benjamin Robert Newton
No Relationships to Disclose
 
Michael Keith Cohenuram
No Relationships to Disclose
 
Kert D. Sabbath
Stock and Other Ownership Interests - Johnson & Johnson
 
Ashita D. Talsania
No Relationships to Disclose
 
Armand Vincent Russo
No Relationships to Disclose
 
Roy S. Herbst
Leadership - Immunocore; Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Bayer; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Foundation Medicine; Genentech/Roche; Genmab; Gilead/Forty Seven; Halozyme; Heat Biologics; HiberCell; I-Mab; Immune-Onc Therapeutics; Infinity Pharmaceuticals; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Ribon Therapeutics; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; STCube Pharmaceuticals Inc.; Symphogen; Takeda; TESARO; Tocagen; Ventana Medical Systems; WindMIL; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Kurt A. Schalper
Consulting or Advisory Role - Agenus; Clinica Alemana; Dynamo Therapeutics; EMD Serono; Excite International; Merck; Ono Pharmaceutical; Pierre Fabre; Shattuck Labs; Takeda; Torque
Speakers' Bureau - Bristol-Myers Squibb; BTIG; Fluidigm; Genmab; Merck; Peerview; Takeda
Research Funding - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; Moderna Therapeutics; Navigate BioPharma; Pierre Fabre; Ribon Therapeutics; Surface Oncology; Takeda; Tesaro
Patents, Royalties, Other Intellectual Property - Patent No. 16/464,010 (PREDICTION OF RESPONSE TO IMMUNE-MODULATORY THERAPIES)